AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Anacalypsis Therapeutics secures pre-seed funding led by Metavallon VC's Brain Gain Fund to advance AT001, a stapled peptide for LRRK2-associated Parkinson's disease.
Round Type
Seed
GreeceBiotechnologyHealth CareTherapeuticsInvestors
Description
Greece-based Anacalypsis Therapeutics has raised a pre-seed financing round led by Metavallon VC through its Brain Gain Fund to advance AT001, a stapled peptide targeting the LRRK2–FADD protein-protein interaction for Parkinson's disease. The funding will support a key in vivo efficacy study of AT001 in preclinical models and establish proof of concept. Proceeds will also fund Anacalypsis' broader pipeline of therapeutic and biomarker programs. The company was founded around research showing that pathogenic LRRK2 can engage the death-adaptor protein FADD and activate neuronal cell-death signaling.
Fundz sees it the moment Anacalypsis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
Based on industry dataAnacalypsis Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.